Blog
Blog
Why Enterprise AI Feels Like a Disappointment for Life Sciences Teams
You have used tools like ChatGPT. They are fast, helpful, almost fun. Then your company deploys its own AI platform and something feels off. It hedges. It refuses. It does not understand your business, markets, or data. You are not imagining the gap.
Filter posts by:
Blog
Get Ready to Orchestrate a Better Customer Experience
What does orchestration mean for a brand? True orchestration considers a customer’s preferences before communicating with them. Learnings from past interactions and outcomes are used to identify the most relevant action to lead to a rewarding experience for both the customer...
Blog
Can GenAI be Used to Improve Data Operations Efficiency?
The short answer is yes, by powering process automation with GenAI. It’s an approach that hasn’t received as much attention as other GenAI use cases within life sciences, but the results can be very powerful. To illustrate its power, we’ll examine...
Blog
What Does “Good” Look Like in Customer Engagement?
First, what does “omnichannel” mean in life sciences? Omnichannel is a customer-centric strategy leveraging technology, data and analytics across functions to optimize cross-channel engagement. So, why is it so hard to achieve effective customer engagement impact? There are some companies...
Blog
IRA “Negotiations” Price Release: No Big Surprises, But Is the Industry Ready Today and for the Future?
Yesterday, CMS released the results of the first round of “negotiated” prices for the Inflation Reduction Act (IRA).1 The IRA is a historical landmark legislation for the pharmaceutical industry, and the results from these “negotiations” involving 10 of the top Medicare...
Blog
The Next Wave of Global AI Medical Devices: Innovation in Action
A recent bipartisan initiative by Senators Martin Heinrich, Mike Rounds, Marsha Blackburn and Todd Young urged the Centers for Medicare & Medicaid Services (CMS) to establish a formal payment pathway for algorithm-based health care services (ABHS). This move addresses the need...
Blog
Developing Effective Global Value Dossiers
Trinity Life Sciences recently worked with a large global pharma company to develop a new process for creating global value dossiers (GVDs) that better met the needs of regional affiliates. Matt O’Hara, who leads Trinity’s Evidence Strategy practice, shares insights into...
